Shicheng Yang

Shicheng (Steven) Yang is a distinguished professional in the field of tumor immunology with extensive experience in laboratory operations and research leadership. Currently serving as Director in Laboratory Operations at viTToria biotherapeutics since June 2022, Yang focuses on CAR T-based platforms for cancer care. Prior roles include Pre-clinical Lead in Oncology at ChristianaCare Gene Editing Institute, where novel therapeutic strategies for solid tumors were advanced, and Principal Scientist at the National Cancer Institute, specializing in chimeric antigen receptor design for adoptive immunotherapy. Yang's career also encompasses leadership positions in various biotechnology firms and academic institutions, including the establishment of an R&D laboratory and therapeutic pipelines at GenTarGet Biotherapeutics and ZMKS International Cancer Therapy Biotechnologies. Yang's educational background includes a PhD in Tumor Immunology and an MD, underscoring expertise in immunology and gene editing techniques for cancer treatment.